stoxline Quote Chart Rank Option Currency Glossary
Insmed Incorporated (INSM)
56.98  3.43 (6.41%)    05-30 16:00
Open: 54.78
High: 58.81
Volume: 16,111,664
Pre. Close: 53.55
Low: 54.67
Market Cap: 8,468(M)
Technical analysis
2024-05-30 4:42:21 PM
Short term     
Mid term     
Targets 6-month :  68.69 1-year :  80.23
Resists First :  58.81 Second :  68.69
Pivot price 30.45
Supports First :  36.01 Second :  21.92
MAs MA(5) :  40.83 MA(20) :  29.3
MA(100) :  27.8 MA(250) :  25.48
MACD MACD :  4.9 Signal :  1.4
%K %D K(14,3) :  95.4 D(3) :  63.7
RSI RSI(14): 88.2
52-week High :  58.81 Low :  18.77
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ INSM ] has closed above the upper band by 8.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 1033.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 58.9 - 59.14 59.14 - 59.38
Low: 54.12 - 54.35 54.35 - 54.59
Close: 56.59 - 57 57 - 57.43
Company Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Headline News

Thu, 30 May 2024
Behind the Scenes of Insmed's Latest Options Trends - Insmed (NASDAQ:INSM) - Benzinga

Thu, 30 May 2024
Assetmark Inc. Purchases 1116 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World

Wed, 29 May 2024
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data - Yahoo Finance

Tue, 28 May 2024
Insmed Announces Proposed $500 Million Public Offering of Common Stock - Yahoo Finance

Tue, 28 May 2024
Insmed stock blasts off over lung condition study results - Yahoo Finance

Tue, 28 May 2024
Insmed stock surges on Phase 3 trial win (NASDAQ:INSM) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 149 (M)
Shares Float 147 (M)
Held by Insiders 1 (%)
Held by Institutions 105 (%)
Shares Short 8,530 (K)
Shares Short P.Month 9,040 (K)
Stock Financials
EPS -5.35
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.14
Profit Margin -236.8 %
Operating Margin -208.5 %
Return on Assets (ttm) -31.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 15.8 %
Gross Profit (p.s.) 0
Sales Per Share 2.12
EBITDA (p.s.) -4.53
Qtrly Earnings Growth 0 %
Operating Cash Flow -574 (M)
Levered Free Cash Flow -415 (M)
Stock Valuations
PE Ratio -10.68
PEG Ratio 0
Price to Book value -18.21
Price to Sales 26.83
Price to Cash Flow -14.76
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android